Krishnan
@krishnaniyer199
Followers
37
Following
1K
Media
0
Statuses
149
Joined January 2010
Our most recent work provides strong rationale for combination of KRAS inhibitors & anti-CTLA4 in clinical trials. https://t.co/eKJezOAqBs KRASi synergize with anti-CTLA4 to prevent resistance by epigenetic reprogramming of Tregs & TLS recruitment. @Aiims1742 @KalluriLab
biorxiv.org
Lack of sustained response to oncogenic Kras (Kras*) inhibition in preclinical models and patients with pancreatic ductal adenocarcinoma (PDAC) emphasizes the need to identify impactful synergistic...
2
2
7
A truly heroic team effort 💪 by more than 90 colleagues across 17 departments, cores, and offices from start of finish, including manufacturing of clinical GMP grade drug and non-human primate studies. Only possible at @MDAndersonNews
1
1
4
Heavy lifting by @Val_LeBleu @drsmags @DrShubhamPant @EJShpallMD @Aiims1742 @rkalluriMDPhD @krishnaniyer199 @mcandrews_kate @loukirtley @cara_haymaker @MikeGagea @abhinavjain_phd @rachnatshroff and other co-authors not online 🤩
1
2
8
🎉 It’s Official! Our phase 1️⃣ trial of iExosomes in metastatic pancreatic cancer is now published in @NatureComms Zero DLTs in this first-in-human trial of systemically administered engineered exosomes targeting KRAS G12D ‼️ Phase 2️⃣ is underway! https://t.co/6AdEqYLRJ0
nature.com
Nature Communications - iExoKrasG12D are engineered exosomes for the delivery of siRNA targeting KRASG12D. Here the authors describe the results of a phase I trial of iExoKrasG12D in patients with...
4
13
36
📣Coming Soon: Extracellular Vesicles and Exosomes Biology Core Facility (EVcore) A first of its kind facility to support your EV research needs including isolation, characterization, imaging, engineering and more. Grateful to @CPRITTexas for supporting this resource. Stay
6
20
111
@timheff5 Find companion manuscript in pre-print with iExosomes targeting KRAS sensitising PDAC to anti-CTLA4 therapy. Detailed characterization of iExo in non-human primates & phase1 trial data with direct clinical relevance. https://t.co/C801YbL9jV
@KalluriLab
medrxiv.org
Oncogenic KRAS drives initiation and maintenance of pancreatic ductal adenocarcinoma (PDAC). Here, we show that engineered exosomes with KrasG12D specific siRNA (iExoKrasG12D) reveal impressive...
0
0
0
KRASG12D-Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC Patients https://t.co/1auQDmn8N3 First in human personalized medicine with exosomes! @KalluriLab @Aiims1742
medrxiv.org
Oncogenic KRAS drives initiation and maintenance of pancreatic ductal adenocarcinoma (PDAC). Here, we show that engineered exosomes with KrasG12D specific siRNA (iExoKrasG12D) reveal impressive...
0
6
11
ScATAC/RNA seq and demonstrate downregulation of AP1 TFs on IL10 & IL35 promoter/enhancer regions in Tregs of KRASi+aCTLA4 treated PDAC. TLS in combination therapy show expansion of germinal center, IFN stimulated Bcells and plasma cells. Great team effort with @Bingruilii
0
0
1
Many thanks to @DeNardoLabWUSM for their spotlight article on our cDC1 vaccine. 👉 https://t.co/2d6N2wp5jO ICYMI: our work in @ScienceMagazine by @krishnaniyer199 and colleagues: cDC1 vaccine facilitates curative immunotherapy in PDAC. 👉
0
3
8
Really nice focus article from Dr. Denardo and colleagues @DeNardoLabWUSM
https://t.co/yIyTWDQxiZ
0
0
1
I am happy to share the latest paper from Goswami_Lab in Nature Immunology. We showed the integration of metabolic & epigenetic pathways regulating CD8 T cell mediated anti tumor immunity via histone lactylation. @DeblinaRC@RaiPratishtha@MDAndersonNews
26
31
244
A huge thank you to my mentor Dr.Kalluri @rkalluriMDPhD and Dr.LeBleu @Val_LeBleu. I cannot make it without the support of Kalluri lab @KalluriLab.
💥Check out our latest!! Vascular heterogeneity of tight junction Claudins guides organotropic metastasis. We show that “it’s not the car, it’s the highway” 💥NOW ONLINE in @NatureCancer
https://t.co/4XZN5MXQPr
1
2
10
Excellent news article from ACIR highlighting our cDC1 work https://t.co/G0vQBYYGeV
acir.org
Pancreatic ductal adenocarcinoma (PDAC) remains refractory to immunotherapy due to a compromised tumor immune microenvironment (TIME) with dysfunctional T cells, suppressive myeloid and regulatory T...
0
0
0
In @ImmunityCP, Raghu Kalluri discusses the role of extracellular vesicles (EVs) in immune response and immunity. Might EVs be the original primordial units preceding creation of the first cell? https://t.co/hsSx0VRt3r
0
7
42
Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. @KalluriLab @MDAndersonNews 👏👏👏
sciencemagazinedigital.org
INTRODUCTION: Sites of chronic tissue injury and inflammation demonstrate an increased propensity to develop cancers.
0
4
21
New @ScienceMagazine publication from @KalluriLab @MDAndersonNews Type I conventional dendritic cells facilitate immunotherapy in #PancreaticCancer
https://t.co/d2IufYhvF4 How is the tumor immune microenvironment of pancreatic cancer associated with pancreatitis (ptPDAC)
0
35
122
cDC1 vaccine facilitates curative immunotherapy in Panvreatic cancer. Our work from @KalluriLab @rkalluriMDPhD published in @ScienceMagazine today. Thanks to a great collaboration with @swatowic lab and Allison on our work. https://t.co/i7l42KfGJR.
science.org
Inflammation and tissue damage associated with pancreatitis can precede or occur concurrently with pancreatic ductal adenocarcinoma (PDAC). We demonstrate that in PDAC coupled with pancreatitis...
4
0
7
"Immunotherapies alone have made little impact against pancreatic cancer, but new research suggests combining them with KRAS-G12D inhibition may hold the key to durable responses." 2 out of the 3 papers referenced are from our group (and collaborators)! https://t.co/blGWn0ENPn
nature.com
Immunotherapies alone have made little impact against pancreatic cancer, but new research suggests combining them with KRAS-G12D inhibition may hold the key to durable responses.
0
2
15
From a combination therapy for KRAS-mutated pancreatic cancer to potential targets for improving stomach cancer treatment to recent highlights from #ESMO23, learn about our latest research: https://t.co/xBgwA5EErM
@RonDePinho #PancreaticCancer #GastricCancer #EndCancer
0
3
17